- Détails du magazine
- Première publication
- 25 Nov 2011
- Période de publication
- 2 fois par an
- Accès libre
Pages: 1 - 9
Phospholipid-based non-viral carriers composed of neutral phospholipid dioleoylphosphatidylethanolamine (DOPE) and the binary mixture DOPE–oleic acid (OA) are examined as potential DNA delivery vectors. The process of DNA condensation in the presence of Ca2+ ions has been monitored through changes in emmision intensity of fluorescent probe ethidium bromide. The decline in fluorescence intensity with increasing Ca2+ concentration at two different time intervals was correlated with the binding capacity of complexes and possible release of DNA from the complex. The microstructure of DOPE–OA mixtures at different OA/DOPE molar ratios and that of DOPE–OA–DNA–Ca2+ complexes were determined using synchrotron small angle X-ray diffraction (SAXD). We identified inverted hexagonal phase HII as the dominant structure. OA affects the lattice parameter of HII formed by DOPE. With the increasing OA/DOPE molar ratio, the lattice parameter decreases, which results in significantly lower fraction of DNA bound to the OA-enriched complexes.
- oleic acid
- Accès libre
The estimation of competitive positions of non-steroid anti-inflammatory drugs on pharmaceutical market of Ukraine
Pages: 10 - 14
The aim of our analysis is the estimation of non-steroid anti-inflammatory drugs (NSAID) competitiveness level, calculation of capacity, share and saturation of studied segment of market that allow to improve the competitive strategies of pharmaceutical manufacturing enterprises.
MATERIALS AND METHODS: According to the results of content-analysis of foreign and native economic literature, we elaborated the methodology of estimation of NSAID competitive positions that consists of six main stages. The offered model of estimation of competitiveness of the studied group of medicines is based on the construction of competition map of medicines on the example of non-selective NSAID as the largest group by the number of presented trade names (TN) using the calculation of market share of medicines for 2015-2016 and dynamics of its growth.
RESULTS: The results of NSAID TN distribution in groups according to the market share volume testify that only 8 TN of medicines among 74 are the leaders of market and 10 TN are characterized with strong competitive position. At the same time 51 NSAID TN are outsiders and 5 TN have weak competitive position.
The results of NSAID TN distribution in groups according to the change of their competitive position allow state that 16 TN among 74 have fast worsening competitive position, 43 TN belong to the group with worsening competitive position and only 5 TN has competitive position, characterized by fast improvement.
CONCLUSION: The analysis of position, occupied by NSAID TN in matrix, demonstrated that 8 TM of medicines are the leaders of the market. At the same time 51 medicines TN are outsiders. The results of research demonstrated that 59 NSAID TN are characterized with worsening and fast worsening competitive positions.
- pharmaceutical market
- non-steroid anti-inflammatory drugs
- market share
- competition map
- Accès libre
Support of medication adherence by community pharmacists in Czech and Slovak Republics: a questionnaire survey study
Pages: 15 - 23
- community pharmacy
- medication adherence
- Czech and Slovak Republics
- Accès libre
Restriction on the re-export of medicinal products and the supervision of compliance with it by public administration bodies
Pages: 24 - 30
After years of mainly expert discussions (not only in the Slovak legal environment), the concept of and legislation on re-export offer a sort of solution provided for in the Act no. 306/2016 Coll. Said act amends the key legislation in this field, namely the Act no. 362/2011 Coll. on Medicinal Products and Medical Devices and on the amendment of certain acts, as amended (hereinafter referred to as the “Act on Medicinal Products”) and the Act no. 363/2011 Coll. on the Scope and Conditions of Payments for Medicinal Products, Medical Devices and Dietetic Foods from Public Health Insurance and on the amendment of certain acts, as amended (hereinafter referred to as the “Act on Payments”). The topic of the paper belongs in the area of medicinal products and pharmaceutical services, it offers, however, significant overlaps in the area of the constitutional, administrative and European law and is aimed at multidisciplinary research into the issue of the reverse export (re-export) of medicinal products. Besides these laws, also the Constitution of the Slovak Republic (“SR”) and the sources of the European Law have to be taken into account in relation to the subject in question. The main aim of legislation in this area of law was restriction on the re-export of selected products and protection of patients from adverse impacts of such business activity. The aim of the paper is the authors’ effort to analyse the issue of the re-export of medicinal products within the context of the adopted Act no. 306/2016 Coll., whose legislative solution is inevitable for the protection of life and health of the population of the Slovak Republic.
- Re-export of medicinal products
- pharmaceutical services
- protection of life and health
- right to free enterprise
- administrative law
- Accès libre
Pages: 31 - 35
Aim: Sildenafil citrate is a drug used to treat erectile dysfunction (ED) and pulmonary arterial hypertension (PAH). As for both clinical applications, the only available dosage form is tablets; there is a clear need for a safe oral liquid, especially for children. The objective of this study was to determine the stability of sildenafil citrate in SyrSpend® SF PH4, a suspending agent containing neither sorbitol nor alcohol.
Material/Methods: The studied sample was compounded into a 2.5-mg/mL suspension and stored in low-actinic plastic bottles at temperatures between 2 and 8°C and at room temperature conditions. Six samples were assayed at each time point out to 92 days by a high-performance liquid chromatography (HPLC) method. The method was validated for its specificity through forceddegradation studies.
Results: The samples remained within 90–110% of the initial concentration throughout the course of the study. Conclusions: On the basis of the data collected, the beyond-use date of this product is at least 92 days when protected from light at both refrigerated and room temperature storage conditions.
- Oral suspension